Loading
Spanish haematologist who led the PETHEMA trials that tailored acute promyelocytic leukaemia treatment to relapse risk, and who chaired the European LeukemiaNet recommendations for the disease.
Miguel Sanz is a haematologist at Hospital La Fe in Valencia and a founder of the Spanish PETHEMA cooperative group. He led the PETHEMA LPA trials that established risk-adapted ATRA and anthracycline therapy for acute promyelocytic leukaemia and defined the Sanz risk score based on white cell and platelet counts. He was first author of the 2019 Blood update of the European LeukemiaNet recommendations for managing the disease.
Shares Acute promyelocytic leukaemia, Acute myeloid leukaemia and the tag leukaemia.
Shares Acute promyelocytic leukaemia, Acute myeloid leukaemia.
Shares Acute promyelocytic leukaemia, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia and the tag leukaemia.
Shares Acute myeloid leukaemia and the tag leukaemia.
Shares Acute myeloid leukaemia and the tag leukaemia.
Shares Acute myeloid leukaemia and the tag guidelines.
Shares Acute myeloid leukaemia and the tag leukaemia.